Oppenheimer & Co. Inc. Reduces Stock Position in Gilead Sciences, Inc. $GILD

Oppenheimer & Co. Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 268,104 shares of the biopharmaceutical company’s stock after selling 25,216 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Gilead Sciences were worth $32,907,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Csenge Advisory Group raised its stake in shares of Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. raised its stake in shares of Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after buying an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd raised its stake in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after buying an additional 42,200 shares in the last quarter. Finally, TriaGen Wealth Management LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth $1,274,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA granted priority review for Gilead’s once‑daily bictegravir + lenacapavir HIV single‑tablet regimen, with a PDUFA action date in August—this materially shortens the timeline to U.S. commercialization if approved and is a clear near‑term revenue/catalyst driver. U.S. FDA Grants Priority Review
• Positive Sentiment: Morgan Stanley raised its price target to $175 and maintained an Overweight rating — a high‑profile analyst upgrade that can attract institutional and momentum buying. Morgan Stanley Price Target Raise
• Positive Sentiment: Gilead completed the acquisition of Arcellx (~$7.8B), adding the anito‑cel cell therapy to its oncology pipeline — expands long‑term growth optionality beyond antivirals. Gilead Completes Arcellx Acquisition
• Positive Sentiment: Coverage and market writeups are bullish ahead of earnings — analysts and outlets flag a combination of beat potential and multi‑year technical breakout narratives that can fuel momentum flows. Wall Street Outlook
• Neutral Sentiment: Gilead announced several upcoming investor presentations (BofA, RBC, Bernstein, Goldman Sachs) in May — opportunities to refresh guidance/MSG to investors but not immediate revenue drivers. Investor Conference Schedule
• Neutral Sentiment: Estimates tweaked: Erste Group trimmed FY2026 EPS slightly but lifted FY2027 — minor modeling adjustments that leave consensus largely intact. Erste Group Estimate Changes
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (~$1.29M) under a pre‑arranged 10b5‑1 plan. Insider sales can create short‑term headline pressure despite being routine and pre‑planned. CEO Insider Sale Filing
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking greater transparency on patent exclusivities — introduces governance/IP scrutiny that could raise uncertainty around exclusivity‑dependent revenues. AHF Shareholder Resolution

Gilead Sciences Stock Performance

Shares of GILD stock opened at $130.84 on Friday. The stock’s fifty day simple moving average is $140.49 and its 200-day simple moving average is $132.35. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The company has a market capitalization of $162.40 billion, a price-to-earnings ratio of 19.33, a P/E/G ratio of 1.70 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares in the company, valued at $24,835,883.36. This represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,640 shares of company stock worth $26,584,250 in the last 90 days. 0.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GILD shares. Truist Financial boosted their price objective on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Wolfe Research lifted their target price on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Morgan Stanley lifted their target price on Gilead Sciences from $171.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday. Royal Bank Of Canada lifted their target price on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Finally, Leerink Partners lifted their target price on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.